The Role of Dynamics and Allostery in the Inhibition of the eIF4E/eIF4G Translation Initiation Factor Complex.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27162083)

Published in Angew Chem Int Ed Engl on May 10, 2016

Authors

Nicola Salvi1,2, Evangelos Papadopoulos3, Martin Blackledge4, Gerhard Wagner5

Author Affiliations

1: Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, USA. nicola.salvi@ibs.fr.
2: Univ. Grenoble Alpes, CNRS, CEA, Institut de Biologie Structurale, Grenoble, France. nicola.salvi@ibs.fr.
3: Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, USA.
4: Univ. Grenoble Alpes, CNRS, CEA, Institut de Biologie Structurale, Grenoble, France.
5: From the Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, Gerhard_wagner@hms.harvard.edu.

Articles cited by this

Dynamic personalities of proteins. Nature (2007) 8.92

mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science (2010) 4.81

Translational control in cancer. Nat Rev Cancer (2010) 4.59

Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell (2007) 3.21

Cap-dependent translation initiation in eukaryotes is regulated by a molecular mimic of eIF4G. Mol Cell (1999) 3.21

eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A (2010) 3.13

4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res (2007) 2.67

Identification of slow correlated motions in proteins using residual dipolar and hydrogen-bond scalar couplings. Proc Natl Acad Sci U S A (2005) 2.35

Generalized correlation for biomolecular dynamics. Proteins (2006) 2.17

Targeting the translation machinery in cancer. Nat Rev Drug Discov (2015) 1.98

eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res (2009) 1.58

p53-dependent translational control of senescence and transformation via 4E-BPs. Cancer Cell (2009) 1.51

Anti-oncogenic potential of the eIF4E-binding proteins. Oncogene (2012) 1.29

Tumor suppression by small molecule inhibitors of translation initiation. Oncotarget (2012) 1.17

Taking aim at translation for tumor therapy. J Clin Invest (2007) 0.94

Molecular mechanism of the dual activity of 4EGI-1: Dissociating eIF4G from eIF4E but stabilizing the binding of unphosphorylated 4E-BP1. Proc Natl Acad Sci U S A (2015) 0.92

Molecular architecture of 4E-BP translational inhibitors bound to eIF4E. Mol Cell (2015) 0.91

Structural insights into the allosteric effects of 4EBP1 on the eukaryotic translation initiation factor eIF4E. J Mol Biol (2011) 0.90

Targeting the mTOR/4E-BP pathway in endometrial cancer. Clin Cancer Res (2011) 0.90

Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis. Mol Cancer Ther (2010) 0.87

Structure of the eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G. Proc Natl Acad Sci U S A (2014) 0.85

4EGI-1 targets breast cancer stem cells by selective inhibition of translation that persists in CSC maintenance, proliferation and metastasis. Oncotarget (2014) 0.84